Biodesix Closes Series D Financing - July 2011
Biodesix has closed a $20 million series D financing. The new capital will support ongoing commercialization activities for the company's Veristrat.
×
254 Results
Biodesix has closed a $20 million series D financing. The new capital will support ongoing commercialization activities for the company's Veristrat.
Biodesix is one of 30 companies chosen to present at the regional conference held biennially by the Colorado BioScience Association (CBSA).
Publication announced today: Changes in plasma mass-spectral (VeriStrat) profile in course of treatment of NSCLC patients with EGFR-TKIs.
A retrospective analysis of serum samples from the phase III study, EGF30008, will be presented at the 34th Annual San Antonio Breast Cancer Symposium SABCS.
BioConference Live has selected Biodesix to present at the 5th annual Life Sciences conference, taking place online on October 26–27.
Data show that VeriStrat was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies.
The initiation of two strategic partnerships that will provide cancer patients greater and more convenient options for completing VeriStrat testing.
Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute.
Biodesix has received the clinical laboratory evaluation program certification from the New York State Department of Health’s Wadsworth Center.
Biodesix announced that the U.S. Patent & Trademark Office has issued four patents for the protection of the company's products and technology.